Hyphens Pharma Pte. Ltd. has entered into an out-licensing agreement for its skin barrier cream, Cerapro® MED Skin Barrier Cream, covering six European countries.

• Expansion: The agreement grants exclusive commercialisation rights to Swiss dermatology company Louis Widmer SA across Switzerland, Liechtenstein, Austria, Belgium, Luxembourg, and the Netherlands.
• Product Focus: Cerapro® MED is a CE-marked medical device formulated to support skin barrier function and is intended for the management of dermatological conditions such as atopic dermatitis.
• Timeline: The partnership supports planned market entry into the six European markets, subject to local regulatory and commercial requirements. 

This summary is based on a press release issued by Hyphens Group.